Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors

Show full item record



Permalink

http://hdl.handle.net/10138/317829

Citation

Cervera-Carrascon , V , Quixabeira , D C A , Havunen , R , Santos , J M , Kutvonen , E , Clubb , J H A , Siurala , M , Heiniö , C , Zafar , S , Koivula , T , Lumen , D , Vaha , M , Garcia-Horsman , A , Airaksinen , A J , Sorsa , S , Anttila , M , Hukkanen , V , Kanerva , A & Hemminki , A 2020 , ' Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors ' , Molecular Therapy - Oncolytics , vol. 17 , pp. 47-60 . https://doi.org/10.1016/j.omto.2020.03.003

Title: Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors
Author: Cervera-Carrascon, Victor; Quixabeira, Dafne C.A.; Havunen, Riikka; Santos, Joao M.; Kutvonen, Emma; Clubb, James H.A.; Siurala, Mikko; Heiniö, Camilla; Zafar, Sadia; Koivula, Teija; Lumen, Dave; Vaha, Marjo; Garcia-Horsman, Arturo; Airaksinen, Anu J.; Sorsa, Suvi; Anttila, Marjukka; Hukkanen, Veijo; Kanerva, Anna; Hemminki, Akseli
Contributor: University of Helsinki, Department of Pathology
University of Helsinki, Research Programs Unit
University of Helsinki, Medicum
University of Helsinki, Department of Pathology
University of Helsinki, TRIMM - Translational Immunology Research Program
University of Helsinki, Medicum
University of Helsinki, Research Programs Unit
University of Helsinki, TRIMM - Translational Immunology Research Program
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Helsinki In Vivo Animal Imaging Platform (HAIP)
University of Helsinki, Department of Chemistry
University of Helsinki, Division of Pharmacology and Pharmacotherapy
University of Helsinki, Regenerative pharmacology group
University of Helsinki, Helsinki In Vivo Animal Imaging Platform (HAIP)
University of Helsinki, Department of Pathology
University of Helsinki, Research Programs Unit
University of Helsinki, Department of Oncology
Date: 2020-06-26
Language: eng
Number of pages: 14
Belongs to series: Molecular Therapy - Oncolytics
ISSN: 2372-7705
URI: http://hdl.handle.net/10138/317829
Abstract: Despite some promising results, the majority of patients do not benefit from T-cell therapies, as tumors prevent T-cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcome many of the barriers currently facing T-cell therapies of solid tumors. This study aims to understand how four different oncolytic viruses (adenovirus, vaccinia virus, herpes simplex virus and reovirus) perform in that task. For that purpose, an immunocompetent in vivo tumor model featuring adoptive tumor-infiltrating lymphocyte (TIL) therapy was used. Tumor growth control (p
Subject: ADENOVIRUS
ANTITUMOR EFFICACY
CANCER
CARCINOMA
COMBINATION
EPITOPES
IMMUNITY
REOVIRUS
REPLICATION
SUPPRESSION
116 Chemical sciences
319 Forensic science and other medical sciences
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S2372770520300243_main.pdf 5.166Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record